Hormonal contraception in women with migraine: is progestogen-only contraception a better choice? by unknown
Nappi et al. The Journal of Headache and Pain 2013, 14:66
http://www.thejournalofheadacheandpain.com/content/14/1/66REVIEW ARTICLE Open AccessHormonal contraception in women with migraine:
is progestogen-only contraception a better
choice?
Rossella E Nappi1,2,5*, Gabriele S Merki-Feld3, Erica Terreno1,2, Alice Pellegrinelli1,2 and Michele Viana4Abstract
A significant number of women with migraine has to face the choice of reliable hormonal contraception during
their fertile life. Combined hormonal contraceptives (CHCs) may be used in the majority of women with headache
and migraine. However, they carry a small, but significant vascular risk, especially in migraine with aura (MA) and,
eventually in migraine without aura (MO) with additional risk factors for stroke (smoking, hypertension, diabetes,
hyperlipidemia and thrombophilia, age over 35 years). Guidelines recommend progestogen-only contraception as
an alternative safer option because it does not seem to be associated with an increased risk of venous
thromboembolism (VTE) and ischemic stroke.
Potentially, the maintenance of stable estrogen level by the administration of progestins in ovulation inhibiting
dosages may have a positive influence of nociceptive threshold in women with migraine. Preliminary evidences
based on headache diaries in migraineurs suggest that the progestin-only pill containing desogestrel 75 μg has a
positive effect on the course of both MA and MO in the majority of women, reducing the number of days with
migraine, the number of analgesics and the intensity of associated symptoms. Further prospective trials have to be
performed to confirm that progestogen-only contraception may be a better option for the management of both
migraine and birth control. Differences between MA and MO should also be taken into account in further studies.
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Migraine is a disabling headache, characterized by moder-
ate to severe head pain, usually accompanied by nausea,
photophobia, phonophobia and osmophobia (migraine
without aura, MO). In about 30% of patients migraine at-
tacks are preceded by transient focal neurologic symptoms
which are called aura (migraine with aura, MA). Migraine
has a high socio-economical impact. In fact during mi-
graine attacks most migraineurs reported severe impair-
ment or the need of the bed rest and almost 40% of
migraine patients have five or more headache days
monthly [1]. The Global Burden of Disease survey 2010* Correspondence: renappi@tin.it
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in any medium, provided the original work is p(GBD) recently published showed that migraine is the
seventh highest cause of disability in the world [2].
Review
In the last few years significant advance in the field of
reversible hormonal methods has been achieved in order
to maximize the benefits and to minimize the risks.
We believe it is relevant for clinical practice to briefly
review in here potential vascular risks according to the
category of migraine, with and without aura, and to the
type of hormonal contraceptive option.
Epidemiology of migraine and combined hormonal
contraceptive (CHC) use
Migraine affects about 18% of women and 6% of men in
USA and Western Europe [3,4] and its cumulative lifetime
prevalence is 43% in women and 18% in men [5]. It is thenn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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ing the fertile period of the women’ life with a peak of
prevalence in their 20s and 30s [6]. The reproductive life
is characterized by the need of reliable and convenient
methods of contraception. Among the several forms of
contraceptives available, hormonal contraceptives are the
most popular reversible method, both in USA and Europe
and the “Pill” is the most used [7-9]. Low dose [20 to
30 μg ethynil estradiol (EE2) per day] combined hormonal
contraceptives (CHCs) have become the method of choice
and the availability of new progestins (third- and fourth-
generation) has allowed to achieve non-contraceptive
benefits in comparison to older progestins (second –
generation) [10]. CHCs are available in several regimens
and routes of administration (oral, transdermal vaginal) in
the attempt to improve tolerability, adherence and con-
venience of use [11]. Moreover, two new CHCs containing
natural estradiol (E2), instead of EE2, have been intro-
duced to increase safety and future developments are on-
going [12]. Interestingly, many gynecological conditions
that are comorbid with migraine can be treated with
CHCs. This enhances the likelihood of their use in mi-
graine population [13]. The prescription of CHCs may
have different effects on migraine with not univocal results
because of many methodological limitations (diverse hor-
monal combinations, variable research settings, retro-
spective and/or cross-sectional designs, lack of a clear
phenotyping of the headache according to IHS criteria, in-
adequate duration of observation) [14-16]. Historically,
combined oral contraceptive (COCs) is the category best
studied in migraineurs with an aggravation of migraine
reported in 18-50% of cases, an improvement in 3-35%
and no change in 39-65% [17]. A more recent cross-
sectional study on a large population found that migraine
is significantly associated with COCs assumption. Yet
because of the design of the study it is not possible to de-
fine a causal relationship between exposure and disease
[18]. Analysis on the different effect of the COCs on the
two forms of migraine revealed that MA worsen more
(56.4%) than MO (25.3%) [19]. Furthermore, women can
present MA for the first time during the initiation of
COCs [20]. During the last decade, a specific “window” of
vulnerability triggered by the 7 days free hormone interval
has been identified and the definition of hormonally-
associated headaches (exogenous hormone-induced head-
ache and estrogen-withdrawal headache) encompasses
several patho-physiological mechanisms which are likely
to explain nociceptive threshold in women [21,22]. Strat-
egies to minimize estrogen withdrawal at the time of
expected bleeding or to stabilize circulating estrogen at
lower concentration include, respectively, 1) to use trans-
dermal E2 during the free interval of hormonal contracep-
tion [22] or to shorten the interval from 7 to 4 and even
to 2 days [23,24]; 2) to administer low dose COCs inextended/flexible regimens [25] or to use extended vaginal
contraception [26].
Very recently, Mac Gregor [27] reviewed the effects of
currently available contraceptive methods in the context
of the risks and benefits for women with migraine and
non-migraine headaches and concluded that for the ma-
jority of women with headache and migraine, the choice
of contraception is unrestricted. Indeed, the contracep-
tive method is unlikely to have an impact on headache,
whereas migraine deserves accurate diagnosis and rec-
ognition of the impact of different methods on such
condition.
Vascular risks associated with CHCs and migraine
MA, and to a lesser extent also MO, may increase vascular
risk, especially the risk for ischemic stroke in younger
women [27-30]. Moreover, evidences that need to be cor-
roborated by further studies suggest an association be-
tween MA and cardiac events, intracerebral hemorrhage,
retinal vasculopathy and mortality [31]. Even though the
association between migraine and stroke appears to be
independent of other cardiovascular risk factors [32], the
presence of some risk factors, such as smoking and/or
COCs use or their combination, further increase risk [33].
MA is associated with a twofold increased risk of ischemic
stroke but the absolute risk associated with CHC use is
very low in healthy young women with no additional risk
factors and mostly related to the estrogen dose [34]. In
spite of the considerable advances in terms of safety and
tolerability of CHCs in migraine sufferers [13], their use is
still questioned especially in women with additional risk
factors for stroke, including, smoking, hypertension, dia-
betes, hyperlipidemia and thrombophilia, age over 35 years
[35]. New evidences [36-38] have warned clinicians on the
use of CHCs and the risk of venous thromboembolism
(VTE) which is likely to be dependent on the type
of the progestin [RR 1.6–2.4 by using third- and
fourth-generation CHCs (namely, desogestrel, gestodene
norgestimate and drospirenone, respectively) in compari-
son with those containing LNG (second-generation)] and
the total estrogenicity of CHCs [39,40]. Even new routes
(trandermal patch and vaginal ring) seem to be associated
with an increased VTE risk, but data are contradictory
[41-43]. Indeed, according to a statement very recently re-
leased [44] many factors contribute to VTE risk (e.g. age,
duration of use, weight, family history) which makes epi-
demiological studies vulnerable to bias and confounders.
In addition, the decision-making process should take into
account non only the small VTE risk (absolute risk de-
pending on the background prevalence rate between 2 to
8 per 10,000 users per year [45]) of the contraceptive
method but also other elements such as efficacy, tolerabil-
ity, additional health benefits, and acceptability which have
to be discussed with the individual woman. In any case, it
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avoiding the prescription of CHCs to women at elevated
risk for VTE. In the context of migraine and CHCs use, it
is very important to remember that the World Health
Organization Medical Eligibility Criteria for Contraceptive
Use stated that MA at any age is an absolute contraindica-
tion to the use of COCs (WHO Category 4) [46]. The US/
WHO MEC is more restrictive than the UK/WHO MEC
as regard to MO, rating CHCs as a category 4 for any
migraineur over age 35 [47]. That being so, the personal
risk assessment should guide the prescription of CHCs in
selected conditions. When there is the sole need of contra-
ception, without the added benefits of a peculiar hormonal
compound and/or combination, CHCs with the lower vas-
cular risk or alternative methods for birth control should
be considered.
Progestogen-only contraception: a class on its own
The progestin component of hormonal contraceptives ac-
counts for most of their contraceptive effects (inhibition of
ovulation, suppression of endometrial activity, thickening of
cervical mucus). Progestin-only methods includes pills (the
pill most used in Europe contains low doses of desogestrel),
injectables [depot Medroxyprogesteroneacetate (DMPA)],
implants (the most recent long-acting reversible contra-
ception contains Etonogestrel single-rod implant for at
least 3 years), and intrauterine devices (levonorgestrel for
at least 5 years) [48]. By providing effective and reversible
contraception, progestin-only contraception has many
noncontraceptive health benefits including improvement
in dysmenorrhea, menorrhagia, premenstrual syndrome,
and anemia [49]. Indeed, there is a general reduction of
the amount of menstrual bleeding but cycle control may
be erratic, a feature that may influence acceptability
[50-52]. Progestin-only methods are appropriate for
women who cannot or should not take CHCs because
they have some contraindications to estrogen use and
therefore display a higher risk of VTE [35,36]. The
progestogen-only contraception is a safe alternative to
CHCs and the avoidance of the estrogen component has
many advantages not only for breastfeeding women but
also for women with vascular diseases or risk factors for
stroke [46,47]. The use of progestin-only contraception is
not associated with an increased risk of VTE compared
with non-users of hormonal contraception [53]. In
addition, progestin-only pills, injectables, or implants are
not associated with increased risk of ischemic stroke
according to a recent metanalysis (OR 0.96; 95% CI: 0.70-
1.31) [54]. Since the 1-year prevalence rates for migraine
in women are 11% for MO and 5% for MA, respectively
[55], there is potentially a high number of women in
whom CHCs may be contraindicated according to WHO
guidelines and progestogen-only contraception may be
safely used [35,36].Evidence of progestogen-only contraception in women
with migraine
Given the evidence that progestogen-only contraception
is a safer option for women with migraine, the main
question is whether such contraceptive choice may in-
fluence the course of both MA and MO and offer a bet-
ter management of the disease. Indeed, even though the
excess risk of death for a woman taking modern CHCs
is 1 in 100,000, which is much lower than the risk of
everyday activities such as cycling [56], there is a bio-
logical plausibility that in women with migraine should
be wiser to use an estrogen-free containing contracep-
tion to avoid any potential vascular risk. Two recent
very large epidemiologic studies [36,57] reported the as-
sociation between CHC and progestogen-only methods
and cardiovascular risk, thrombo-embolic risk and
stroke. Whereas no increased risk for deep venous
thormbosis, myocardial infarction and thrombotic
stroke was found for the progestogen-only methods, the
risk were two-sixfold elevated in CHC users. The role of
progesterone/progestins in the pathophysiology of mi-
graine has been overshadowed by Somerville’s early ob-
servations that it was the prevention of estrogen but not
of progesterone withdrawal in the late phase of the cycle
to be able to prevent the occurrence of migraine attacks
[58,59]. Indeed, at variance with the influence of estrogens
upon the cerebral structures implicated in the pathophysi-
ology of migraine [60], cyclic variations in progestin levels
were not related to migrainous headaches, but they rather
seem to be protective. Progesterone apparently attenuates
trigemino-vascular nociception [61] and its receptors are
localized in areas of the central nervous system, which are
involved in neuronal excitability and neurotransmitter
synthesis release and transport [62]. It has been shown
that progesterone can antagonize neuronal estrogenic ef-
fects by downregulating estrogen receptors [63]. Whereas
estrogen peak decrease the threshold for cortical spreading
depression (CSD), the neurobiological event underlying
MA, estrogen withdrawal increased the susceptibility to
CSD in an animal model [64]. Therefore, the maintenance
of low estrogen levels and the avoidance of estrogen with-
drawal by the administration of progestins in ovulation
inhibiting dosages might decrease cortical excitability. In-
deed, progestogen-only contraception has a continuous
administration, without the hormone-free interval, and
does not induce withdrawal stabilizing circulating estro-
gens, but some fluctuations according to different prepara-
tions may still occur [65]. Clinical data are scarce and no
comparative studies with progestogen-only contraceptives
and placebo or COCs are available in the literature [27].
Diagnoses are often inaccurate, without distinction be-
tween headache and migraine, and headache is reported in
contraceptive progestin implant users as a potential cause
of discontinuation [66]. Similarly, there is an increase in
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norethisterone enanthate and, especially with depot
medroxyprogesterone acetate [67]. Anecdotally, migraine
is more likely to improve in women who achieve amenor-
rhea [68]. In a large, cross-sectional, population-based
study in Norway of 13944 women, a significant association
between CHC and headaches, but no significant associ-
ation between progestin-only pills and migraine (OR 1.3,
95% CI: 0.9–1.8) was found but the number of users was
small [18]. To date two diary-based studies pilot studies
on the effect of desogestrel 75 μg on migraine have been
published [69,70]. Such oral daily pill inhibits ovulation
and the dose allows the ovary to synthesize stable amounts
of estrogen which are relevant for wellbeing and bone
density [71]. The first study included thirty women with
MA [69]. The use of desogestrel 75 μg resulted in a signifi-
cant reduction in MA attacks and in the duration of aura
symptoms, already after three months of observation.
Interestingly, the beneficial effect of desogestrel 75 μg on
visual and other neurological symptoms of aura was
significantly present only in those women in whom MA
onset was related to previous COCs treatment. These
findings suggest that the reduction in estrogen levels may
be relevant to the amelioration of MA, but do not exclude
a direct effect of the progestin on CSD. The second study
on the effect of desogestrel 75 μg included women with
MA (n°=6) and with MO (n°=32) and evaluated migraine
days, pain score and pain medication [70]. An improve-
ment of each parameter was observed during 3 months
use of desogestrel 75 μg in comparison to a three months
pretreatment interval. A subanalyses of the effect on 32
women with MO revealed significant improvements in
number of migraine days, pain medication and pain inten-
sity. The mean number of migraine attacks at baseline was
higher in comparison to that in the study of Nappi et al.
[69], indicating that also very severe migraineurs might
profit from such a progestin-only contraception. Chronic
migraineurs often develop medication overuse headaches
with severe limitation of their quality of life. The reduction
of pain medication by progestin-only contraception is an
interesting approach and it should be studied further. In-
deed, there is a broad variation in the intensity of improve-
ment with a reduction in migraine frequency ranging
from 20% and 100% [70]. No indicators to identify those
women who will profit from desogestrel 75 μg could be
ascertained. On the other hand, there were few dropouts
of women experiencing more migraine after starting
contraception with this progestin in both studies, indi-
cating that progestins can also deteriorate migraine in few
cases.
A very recent study investigating the changes of quality
of life in migraineurs 3 months after initiation of the
progestagen-only pill desogestrel 75 μg demonstrates a
highly significant reduction in Midas Score and Midasgrades [72]. However, clinical experience with desogestrel
75 μg in migraineurs further shows that during the initial
4 weeks migraine frequency can raise slightly before head-
aches improve. This information has to be mentioned and
discussed during counseling.
In summary, the potential advantages of using
progestogen-only contraception in women with mi-
graine are the following:
1) Continuous use
2) Absence of estrogen peak
3) No influence on threshold for cortical spreading
depression (CDS)
4) No evidence of increase in cardiovascular, stroke
and thrombo-embolic risk
5) No data on progestins inducing migraineConclusions
In conclusion, contraceptive counseling in migraine should
take into account the risk-benefit profile of the individual
woman before prescribing CHCs. In order to reduce
potential vascular risks, recommendations should be a
main point of guidance for prescribers. Progestogen-only
contraception is a safer option in MA and eventually in
MO with additional risk factors. Given preliminary evi-
dences of a positive effect of the progestin-only pill
desogestrel 75 μg on MA and MO in many, but not all
women, further prospective trials have to be performed to
confirm that progestogen-only contraception may be a
better option for the management of both migraine and
birth control. Differences between MA and MO should
also be taken into account in further studies.
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